'Beating heart' technology could revolutionize field of heart transplantation

Dec 06, 2010 By Amy Albin
TansMedics organ-transport device. After a heart is removed from a donor's body, it is placed in a high-tech OCS box and is immediately revived to a beating state, perfused with oxygen and nutrient-rich blood, and maintained at an appropriate temperature.

(PhysOrg.com) -- The heart transplantation team at Ronald Reagan UCLA Medical is currently leading a national, multicenter phase 2 clinical study of an experimental organ-preservation system that allows donor hearts to continue functioning in a near-physiologic state outside the body during transport.

This video is not supported by your browser at this time.

The Organ Care System (OCS), developed by medical device company TransMedics, works this way: After a heart is removed from a donor's body, it is placed in a high-tech OCS box and is immediately revived to a beating state, perfused with oxygen and nutrient-rich blood, and maintained at an appropriate temperature. The device also features monitors that display how the heart is functioning during transport.

The current standard of transporting donor hearts in iceboxes in a non-functioning state, which has been used for decades, requires the restarting of the heart once it has been placed inside the recipient.

"The concept of transplanting a in a beating state is revolutionary," said Dr. Abbas Ardehali, surgical director of the heart and lung transplantation program at Ronald Reagan UCLA Medical Center and principal investigator of the OCS trial. "This promising technology may improve the function of the donor heart, because it remains in a near-physiologic state. It can also help us better assess the suitability of a potential donor, since we can test the heart in the device."

Ardehali said the technology could also lead to better tissue matching between donor hearts and recipients because the box would grant the transplant team more time to test the heart for potential rejection factors.

Additionally, because the current transport method requires a donor heart to be delivered to a recipient within six hours to remain viable, the OCS box could potentially help expand the donor pool by allowing donor hearts to be safely transported across longer distances.

The OCS study led by UCLA will enroll a total of 128 patients nationwide in a randomized, controlled trial comparing the safety and effectiveness of the experimental OCS with the existing icebox method for keeping donor hearts healthy.

Additional study sites include Columbia University, the Cleveland Clinic, Washington University in St. Louis, Tufts Medical Center, Massachusetts General Hospital, Brigham and Women's Hospital, Newark Beth Israel Medical Center, Stanford Hospital and Clinics, the University of Pittsburgh Medical Center, Jackson Memorial Hospital and the University of Washington, Seattle.

"There are not enough donor hearts to help all the patients who are waiting," Ardehali said. "If we can find ways to improve upon our limited supply of hearts, then more lives will be saved."

The OCS clinical trial, called the "Prospective, Randomized, Multicenter Safety and Effectiveness Evaluation of the Organ Care System Device for Cardiac Use" (PROCEED II), is fully designed and sponsored by TransMedics.

Ardehali has no financial ties to disclose.

Explore further: Growing a blood vessel in a week

More information: www.transmedics.com/wt/home/index

add to favorites email to friend print save as pdf

Related Stories

Texas Children's discharges history-making patient

Feb 13, 2010

The wait is over for 16-year-old Francesco "Frank" De Santiago. On January 29, De Santiago received a donor heart in a nine-hour transplant operation at Texas Children's Heart Center De Santiago made news ...

Recommended for you

Growing a blood vessel in a week

Oct 24, 2014

The technology for creating new tissues from stem cells has taken a giant leap forward. Three tablespoons of blood are all that is needed to grow a brand new blood vessel in just seven days. This is shown ...

Testing time for stem cells

Oct 24, 2014

DefiniGEN is one of the first commercial opportunities to arise from Cambridge's expertise in stem cell research. Here, we look at some of the fundamental research that enables it to supply liver and pancreatic ...

Team finds key signaling pathway in cause of preeclampsia

Oct 23, 2014

A team of researchers led by a Wayne State University School of Medicine associate professor of obstetrics and gynecology has published findings that provide novel insight into the cause of preeclampsia, the leading cause ...

Rapid test to diagnose severe sepsis

Oct 23, 2014

A new test, developed by University of British Columbia researchers, could help physicians predict within an hour if a patient will develop severe sepsis so they can begin treatment immediately.

User comments : 0